TuHURA Biosciences, Inc. HURA R2K
Healthcare · Biotechnology · United States
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
READ MORE ›$2.26
-26.14% 1Y
Market & Price
Market Cap
$143.92M
Current Price
$2.26
High / Low (52W)
$3.25 / $0.44
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.35
Price to Book
6.49
P/S
-
EV/EBITDA
-4.78
Dividend Yield
-
Profitability & Returns
ROCE
-137.29%
ROE
-
ROA
-81.88%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.13
EPS (TTM)
$-0.61
Balance Sheet & Liquidity
Debt/Equity
1.97
Quick Ratio
1.07
Current Ratio
1.15
Debt
$456.93K
Total Assets
$27.35M
Current Assets
$4.62M
Working Capital
$-1.30M
Ownership
Promoter Holding
34.88%
Chg in Prom Hold
-
FII / Inst Holding
14.98%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$138.36M
Total Revenue (TTM)
-
EBITDA
$-28.97M
Free Cash Flow
$-1.62M
Operating Cash Flow
$-27.30M
Shares Outstanding
63.68M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-73.60%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -73.6% CAGR over 5 years.
- Trading 30.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HURA TuHURA Biosciences, Inc. R2K | 2.26 | - | $143.92M | - | -137.29% | - | - | -73.60% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.35M | 9.55M | 6.59M | 4.38M | 7.53M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.35M | -9.55M | -6.59M | -4.38M | -7.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.65M | -9.51M | -7.06M | -6.13M | -7.49M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 16.53K | 608.75K | 27.97K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.66M | -9.52M | -7.10M | -6.76M | -7.54M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.79M | 865.98K | -3.20M | -1.52M | -619.63K | 437.58K | -1.62M | - | - | -2.29M | -1.32M | -1.87M | -2.67M | -3.16M | -2.93M | -1.99M | -1.81M | -1.66M | -1.61M | -1.74M | -1.96M | -19.52M | -5.41M | -6.63M | -5.97M | -5.89M | -5.36M | -4.60M | -3.45M | -3.26M | -2.96M | -1.02M | -4.84M | -5.27M | - | -6.66M | -9.52M | -7.10M | -6.76M | -7.54M |
| Diluted EPS | -0.02 | 0.03 | 0.10 | 0.04 | 0.03 | 0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.40 | -0.43 | -0.05 | -0.15 | -0.21 | -0.14 | - | -0.13 |
| R&D Expense | -560.24K | -566.06K | -618.87K | -671.63K | 612.17K | 641.84K | 603.85K | 789.19K | -790.32K | 732.73K | 1.12M | 1.09M | 1.93M | 2.14M | 1.78M | 1.02M | 947.25K | 735.84K | 721.00K | 712.00K | 899.00K | 1.36M | 2.58M | 3.84M | 3.79M | 3.90M | 3.47M | 3.17M | 2.06M | 2.00M | 1.86M | 111.00K | 3.59M | 2.82M | 2.95M | 4.58M | 4.93M | 4.97M | - | 5.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | - | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.72M | - | 13.17M | - | 17.15M | 27.29M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.72M | - | -13.17M | - | -17.15M | -27.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.99M | - | -29.12M | - | -17.43M | -29.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 18.69K | - | 4.14M | 625.28K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.37M | - | -29.32M | - | -21.68M | -30.05M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.33M | -2.40M | -8.29M | 6.36M | -4.35M | 8.86M | 8.08M | 11.14M | -8.05M | -9.13M | -38.30M | - | -22.66M | -9.37M | -14.65M | -29.32M | -8.32M | -21.68M | -30.05M |
| Diluted EPS | - | - | - | 0.00 | 0.11 | - | - | - | - | - | - | - | - | -0.77 | - | -2.47 | - | -1.21 | -0.63 |
| R&D Expense | 1.05M | 1.55M | 2.34M | -2.12M | 2.56M | 3.36M | -5.00M | -7.13M | 3.66M | 3.63M | 11.81M | - | 15.17M | - | 9.31M | 9.40M | 2.66M | 13.34M | 20.53M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -73.60% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -26.14% |
| 6 Months: | +16.49% |
| 3 Months: | +35.33% |
| 1 Month: | +7.62% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Jun 2013 | Dec 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 182.83K | - | 4.32M | 5.00M | 2.58M | 6.36M | 7.91M | 7.07M | 4.04M | 2.94M | 13.54M | - | 15.95M | 15.20M | 3.98M | 4.36M | 6.20M | 19.97M | 27.35M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.74M | - | 4.16M | - | 19.61M | 4.62M |
| Cash & Equivalents | 24.38K | 15.02K | 17.78K | 6.28M | 4.14M | 4.76M | 1.75M | 6.16M | 6.59M | 5.97M | 3.72M | 2.39M | 10.54M | - | 11.78M | 14.25M | 1.53M | 3.67M | 4.91M | 12.66M | 3.62M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 101.42K | - | 334.44K | - | 437.40K | 500.00K |
| Total Liabilities | - | - | 1.51M | - | 5.14M | 5.91M | 3.40M | 1.50M | 1.33M | 1.64M | 2.07M | 2.67M | 2.96M | - | 4.15M | 2.89M | 3.25M | 5.92M | 2.44M | 5.37M | 6.42M |
| Current Liabilities | - | - | 1.13M | - | 249.49K | 299.87K | 853.09K | 627.45K | 1.30M | 1.64M | 2.07M | 2.67M | 2.78M | - | 3.99M | 2.87M | 3.08M | 3.60M | 2.26M | 5.33M | 5.92M |
| Long Term Debt | - | - | - | - | - | - | - | 693.70K | 28.14K | 1.12K | - | - | - | - | - | - | - | 2.32M | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 138.22K | - | 2.34M | - | 202.54K | 700.02K |
| Total Equity | -1.52K | -877.13K | -1.33M | -12.83M | -817.98K | -901.16K | -821.49K | 4.86M | 6.58M | 5.44M | 1.97M | 263.00K | 10.58M | - | 11.79M | 12.30M | 731.00K | -1.56M | 3.76M | 14.59M | 20.93M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.03M | - | 42.03M | - | 42.32M | 59.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.00M | -3.85M | -5.15M | -8.02M | -9.85M | -6.33M | -7.93M | -18.86M | - | -20.39M | -7.51M | -11.87M | -11.95M | -7.18M | -14.73M | -27.63M |
| Investing Cash Flow | - | - | -16.76K | -20.96K | -12.65K | - | - | 964.00K | - | - | -36.28K | -232.00K | -1.30M | -20.00K | -6.05M | -1.34M |
| Financing Cash Flow | 2.48M | 847.79K | 9.57M | 8.47M | 9.25M | 4.07M | 6.60M | 26.04M | - | 21.64M | 16.25M | 1.85M | 2.66M | 10.57M | 29.77M | 19.93M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | -36.28K | - | -79.22K | - | -57.91K | -76.08K |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -7.54M | - | -12.03M | - | -14.79M | -27.71M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 8.71M | - | -10.59M | - | 8.99M | -9.04M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 24.75K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 152.0% | 180.8% | 1,013.6% | -705.6% | 529.3% | 182.5% | 122.9% | 204.9% | -409.0% | -3,470.0% | -362.0% | - | -192.1% | -76.1% | -2,004.0% | 1,880.8% | -221.5% | -148.6% | -143.6% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | -78.9% | - | -1,720.7% | - | -117.2% | -127.3% |
Shareholding Pattern
Insiders
34.88%
Institutions
14.98%
Public Float
23.00%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.85% | 2.45M | $5.54M |
| 2 | Vanguard Capital Management LLC | 3.26% | 2.07M | $4.69M |
| 3 | Geode Capital Management, LLC | 1.55% | 986.92K | $2.23M |
| 4 | AQR Capital Management, LLC | 0.95% | 607.17K | $1.37M |
| 5 | State Street Corporation | 0.81% | 512.91K | $1.16M |
| 6 | Northern Trust Corporation | 0.47% | 298.19K | $673.90K |
| 7 | Vanguard Fiduciary Trust Co | 0.45% | 287.13K | $648.92K |
| 8 | Vanguard Portfolio Management LLC | 0.40% | 253.64K | $573.23K |
| 9 | Bank Of New York Mellon Corporation | 0.33% | 211.57K | $478.14K |
| 10 | Apollon Wealth Management, LLC | 0.25% | 158.01K | $357.10K |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HURA
No recent headlines available.